These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19404518)

  • 21. Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.
    Mital A; Prejzner W; Hellmann A
    Adv Clin Exp Med; 2015; 24(6):1001-6. PubMed ID: 26771972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution.
    Sánchez-Luceros A; Meschengieser SS; Woods AI; Blanco AN; Kempfer AC; Casais P; Salviú MJ; Lazzari MA
    Haematologica; 2002 Mar; 87(3):264-70. PubMed ID: 11869938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of undetermined significance.
    Puronen CE; Josephson NC; Broudy VC
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):430-2. PubMed ID: 23249617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent acquisitions in acquired and congenital von Willebrand disorders.
    Franchini M; Lippi G
    Clin Chim Acta; 2007 Feb; 377(1-2):62-9. PubMed ID: 17140556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombophilic risk factors in epileptic children treated with valproic Acid.
    Unal O; Deda G; Teber S; Ertem M; Akar N
    Pediatr Neurol; 2009 Feb; 40(2):102-6. PubMed ID: 19135623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
    Federici AB; Budde U; Castaman G; Rand JH; Tiede A
    Semin Thromb Hemost; 2013 Mar; 39(2):191-201. PubMed ID: 23397553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of von Willebrand disease type I by valproic acid.
    Kreuz W; Linde R; Funk M; Meyer-Schrod R; Föll E; Nowak-Göttl U; Jacobi G; Vigh Z; Scharrer I
    Lancet; 1990 Jun; 335(8701):1350-1. PubMed ID: 1971412
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
    Sucker C; Michiels JJ; Zotz RB
    Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acquired von Willebrand syndrome associated with Hashitoxicosis and pernicious anemia combined].
    Takai Y; Koya H; Himei S
    Rinsho Ketsueki; 1989 Mar; 30(3):354-60. PubMed ID: 2671435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired von Willebrand Syndrome in Children.
    Sandrock-Lang K; Glonnegger H; Zieger B
    Hamostaseologie; 2022 Apr; 42(2):117-122. PubMed ID: 35488164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new automated screening assay for the diagnosis of von Willebrand disease.
    Salem RO; Van Cott EM
    Am J Clin Pathol; 2007 May; 127(5):730-5. PubMed ID: 17439831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance.
    Castaman G; Tosetto A; Rodeghiero F
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():71-4. PubMed ID: 19630772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefotaxime as the potential cause of transient acquired von Willebrand syndrome.
    Haj MA; Murch N; Bowen DJ; Sati HI; Beddal A; Benton A; Collins P
    Eur J Haematol; 2006 May; 76(5):440-3. PubMed ID: 16529605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe bleeding complications during antiepileptic treatment with valproic acid in children.
    Cannizzaro E; Albisetti M; Wohlrab G; Schmugge M
    Neuropediatrics; 2007 Feb; 38(1):42-5. PubMed ID: 17607605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.